Two-year data from the phase 2 DAZALS trial showed a lower risk of death with dazucorilant 300 mg/day vs placebo in ALS, although the study did not meet its functional primary end point.
Quiz|Articles|November 8, 2026 (Updated: November 3, 2026)
NeurologyLive® Brain Games: November 8, 2026
Author(s)Louie Pasculli
Listen
0:00 / 0:00
Key Takeaways
- Weekly publication cadence is Sunday morning, with content written by physicians, clinicians, and neurological care and advocacy experts.
- Questions span major neurology domains, including dementia/Alzheimer disease, epilepsy, headache, movement disorders, multiple sclerosis, neuromuscular and sleep disorders, and stroke.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery!
Advertisement
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions on a variety of clinical and historical neurology topics, written by physicians, clinicians, and experts in the fields of neurological care and advocacy.
Test your mettle each week with 3 questions that cover a variety of aspects in the field of neurology, with a focus on dementia and Alzheimer disease, epilepsy and seizure disorders, headache and migraine, movement disorders, multiple sclerosis, neuromuscular disorders, sleep disorders, and stroke and cerebrovascular disease.
This week's questions includes the theme of the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery!
Interested in submitting quiz questions? Contact our editor, Marco Meglio, via email:
According to the 2026 AHA/ASA guideline, which statement best reflects the recommendation on mobilization in the acute inpatient setting after stroke?
Which of the following postacute care recommendations in the 2026 guideline carries a Class 3: No Benefit designation?
Which bladder management recommendation in the 2026 guideline carries a Class 1 (strong) recommendation?
How did you do on this week's quiz? Let us know with a response to the poll below. Don't forget to share and compare your results with your friends!
How many questions did you get correct?
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 6, 2026.
Williams, MD, is joined by Marcus Gates, MD, and they discuss recognizing cervical nerve root and spinal cord compression, navigating treatment options, and determining when surgery may be appropriate.
Servier reported that sevasemten did not meet its primary or secondary endpoints in the pivotal GRAND CANYON trial for Becker muscular dystrophy.
QurAlis reported interim ANQUR trial results showing target engagement, a biomarker signal, and a trend toward slower functional decline with QRL-201 in ALS.
An epileptologist at Cleveland Clinic discussed findings from a recently published study of lifestyle interventions in epilepsy and why these approaches should complement rather than replace antiseizure medications.
The 500-participant study will assess whether pridopidine, an investigational sigma-1 receptor agonist, can slow functional decline and improve survival in patients with early, rapidly progressing amyotrophic lateral sclerosis.
Kiril Kiprovski, MD, clinical professor of neurology and director of the Division of Neuromuscular Medicine at NYU Langone, reviews the clinical clues, bedside tests, and referral considerations that help eye care clinicians identify Lambert-Eaton myasthenic syndrome in patients with fluctuating ptosis or diplopia.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
QurAlis Reports ANQUR Interim Data for STATHMIN-2-Targeting Agent QRL-201 in ALS
2
FDA Grants Priority Review to Huntington Disease Gene Therapy BLA, Sevasemten Misses Primary, Secondary End Points in BMD, Overviewing the 1-Year KYSA-8 Findings
3
PREVAiLS Phase 3 Trial Evaluates Pridopidine in Early, Rapidly Progressive ALS
4
ALS Agent Dazucorilant Associated With Lower 2-Year Mortality in Exploratory DAZALS Analysis
5